Tenecteplase Effective for Stroke in Later Time Window Tenecteplase Effective for Stroke in Later Time Window
Patients treated with tenecteplase at up to 24 hours had a threefold higher rate of reperfusion without intracranial hemorrhage than those receiving best medical treatment.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 11, 2024 Category: Cardiology Tags: Neurology & Neurosurgery Source Type: news
When Should a Pediatrician Suspect a Rare Disease? When Should a Pediatrician Suspect a Rare Disease?
Common symptoms expressed in an intense or complicated way, or the presence of many symptoms in the same patient, should raise suspicion of rare disease, said one clinician.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 11, 2024 Category: Neurology Tags: Neurology & Neurosurgery Source Type: news
US FDA Declines to Approve Viatris's Injection for Multiple Sclerosis US FDA Declines to Approve Viatris's Injection for Multiple Sclerosis
The U.S. FDA has declined to approve Viatris and Mapi Pharma ' s once-a-month injection for treating relapsing forms of debilitating neurological condition multiple sclerosis...Reuters Health Information (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 11, 2024 Category: Neurology Tags: Neurology & Neurosurgery Source Type: news
ClearPoint Neuro touts clinical study results
ClearPoint Neuro is highlighting clinical study results that show that its Prism Neuro Laser Therapy system demonstrates "accurate, near real-time temperature of the brain tissue with a mean absolute error of less than 1° C."
Results from the study were published March 8 in the Journal of Neurosurgery and also showed that the morphology of lesions visualized by ClearPoint Neuro's Thermoguide MRI-thermometry software matched histopathology results.
The research was conducted by ClearPoint Neuro and its partner Clinical Laserthermia Systems of Lund, Sweden, the company said. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 11, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Subspecialties Neuroradiology Source Type: news
Amylyx May Pull FDA-Approved ALS Drug Amylyx May Pull FDA-Approved ALS Drug
Topline results for the ALS drug Relyvrio show that it failed to meet primary or secondary endpoints. The company says it may voluntarily pull the drug from the market.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 8, 2024 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery Source Type: news
FDA Delays Decision on Alzheimer's Hopeful Donanemab FDA Delays Decision on Alzheimer's Hopeful Donanemab
In an unexpected move, the FDA has decided to hold an advisory meeting of outside experts to discuss the efficacy and safety of donanemab for Alzheimer ' s disease.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - March 8, 2024 Category: Psychiatry Tags: Neurology & Neurosurgery Source Type: news
Atogepant for Episodic Migraine Prevention: Phase 3 Data Atogepant for Episodic Migraine Prevention: Phase 3 Data
Results of the ELEVATE trial demonstrating the safety and efficacy of oral atogepant for the prevention of treatment-resistant episodic migraine prevention have now been published.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 8, 2024 Category: Neurology Tags: Neurology & Neurosurgery Source Type: news
Most Disadvantaged Least Likely to Receive Thrombolysis Most Disadvantaged Least Likely to Receive Thrombolysis
Black, male, and older ischemic stroke patients are less likely than other populations to antithrombolytic therapy.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 8, 2024 Category: Neurology Tags: Neurology & Neurosurgery Source Type: news
Top Papers From the 2024 International Stroke Conference Top Papers From the 2024 International Stroke Conference
Neurologist Christoph Diener picks his top studies from the 2024 International Stroke Conference.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 7, 2024 Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news
Prodromal Parkinson's and REM Sleep Behavior Disorder Prodromal Parkinson's and REM Sleep Behavior Disorder
Indu Subramanian speaks with REM sleep behavior disorder expert Ron Postuma about when RSD is prodromal Parkinsons ' s disease and new strategies to classify PD.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 7, 2024 Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news
The Power of Patient-Reported Outcomes Inhibited by Barriers The Power of Patient-Reported Outcomes Inhibited by Barriers
Patient-reported outcomes in multiple sclerosis matter but remain underused due to multiple barriers.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 7, 2024 Category: Neurology Tags: Neurology & Neurosurgery Source Type: news
Prognostic Value of sNfL in MS Confirmed Prognostic Value of sNfL in MS Confirmed
ASCLEPIOS sub-studies show high sNfL levels at 3 and 12 months predictive of future CNS activity in patients with multiple sclerosis.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 7, 2024 Category: Neurology Tags: Neurology & Neurosurgery Source Type: news
Signal of Benefit for Stem Cell Therapy in Progressive MS Signal of Benefit for Stem Cell Therapy in Progressive MS
At interim analysis, a stem cell extension study showed favorable clinical and biomarker effects for progressive MS.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 7, 2024 Category: Neurology Tags: Neurology & Neurosurgery Source Type: news
No Support for BTK Inhibitor in Phase 3 MS Trial No Support for BTK Inhibitor in Phase 3 MS Trial
The phase 3 MS trial of the BTK inhibitor evobrutinib was not superior to teriflunomide for any endpoint.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 7, 2024 Category: Neurology Tags: Neurology & Neurosurgery Source Type: news
ACTRIMS 2024: Advances in Disease-Modifying Therapies ACTRIMS 2024: Advances in Disease-Modifying Therapies
Dr Devon Conway reviews discussions on MS disease-modifying therapies, including insights on B-cell therapies.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 6, 2024 Category: Consumer Health News Tags: Neurology & Neurosurgery MDAngle Source Type: news
